While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

Pfizer's booth at the China International Import Expo in Shanghai, Nov. 7, 2024. [Photo by Wang Yiming/China.org.cn] Pfizer ...

The study compared the risk and cumulative incidence of requiring glaucoma surgery—such as minimally invasive surgery, ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The unique feline dermatological cases veterinary professionals can see at the clinic, plus how to approach them ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

ChatGPT recommendations regarding atopic dermatitis (AD) often differ from AAAAI/ACAAI practice parameter recommendations.

Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and CSU. Read why ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Organon (NYSE: OGN), a global healthcare company with a ...